Summary
Global Markets Direct’s, ‘Arrhythmias - Pipeline Review, H1 2016’, provides an overview of the Arrhythmias pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Arrhythmias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Arrhythmias
- The report reviews pipeline therapeutics for Arrhythmias by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Arrhythmias therapeutics and enlists all their major and minor projects
- The report assesses Arrhythmias therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Arrhythmias
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Arrhythmias
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Arrhythmias pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Cynata Therapeutics Limited
Gilead Sciences, Inc.
Ono Pharmaceutical Co., Ltd.
Orion Oyj
SciFluor Life Sciences, LLC
SignPath Pharma Inc
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Arrhythmias Overview 7
Therapeutics Development 8
Pipeline Products for Arrhythmias - Overview 8
Pipeline Products for Arrhythmias - Comparative Analysis 9
Arrhythmias - Therapeutics under Development by Companies 10
Arrhythmias - Therapeutics under Investigation by Universities/Institutes 11
Arrhythmias - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Arrhythmias - Products under Development by Companies 14
Arrhythmias - Products under Investigation by Universities/Institutes 15
Arrhythmias - Companies Involved in Therapeutics Development 16
Cynata Therapeutics Limited 16
Gilead Sciences, Inc. 17
Ono Pharmaceutical Co., Ltd. 18
Orion Oyj 19
SciFluor Life Sciences, LLC 20
SignPath Pharma Inc 21
Arrhythmias - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
aladorian sodium - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Antisense Oligonucleotides to Activate hERG1 for Long-QT Syndrome - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
efsevin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
eleclazine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
EU-8120 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GS-967 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
KN-93 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
landiolol - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
LH-021 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ORM-10103 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
PP-1 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecule for Arrhythmia - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecules to Antagonize Ryanodine Receptor 2 for Ventricular Arrhythmia - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Stem Cell Therapy for Cardiovacular Diseases - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
VKII-86 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Arrhythmias - Recent Pipeline Updates 49
Arrhythmias - Dormant Projects 50
Arrhythmias - Discontinued Products 52
Arrhythmias - Product Development Milestones 53
Featured News & Press Releases 53
May 09, 2014: Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55
List of Tables
Number of Products under Development for Arrhythmias, H1 2016 8
Number of Products under Development for Arrhythmias - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Arrhythmias - Pipeline by Cynata Therapeutics Limited, H1 2016 16
Arrhythmias - Pipeline by Gilead Sciences, Inc., H1 2016 17
Arrhythmias - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 18
Arrhythmias - Pipeline by Orion Oyj, H1 2016 19
Arrhythmias - Pipeline by SciFluor Life Sciences, LLC, H1 2016 20
Arrhythmias - Pipeline by SignPath Pharma Inc, H1 2016 21
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Stage and Target, H1 2016 24
Number of Products by Stage and Mechanism of Action, H1 2016 26
Number of Products by Stage and Route of Administration, H1 2016 28
Number of Products by Stage and Molecule Type, H1 2016 30
Arrhythmias Therapeutics - Recent Pipeline Updates, H1 2016 49
Arrhythmias - Dormant Projects, H1 2016 50
Arrhythmias - Dormant Projects (Contd..1), H1 2016 51
Arrhythmias - Discontinued Products, H1 2016 52
List of Figures
Number of Products under Development for Arrhythmias, H1 2016 8
Number of Products under Development for Arrhythmias - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Targets, H1 2016 23
Number of Products by Stage and Targets, H1 2016 23
Number of Products by Mechanism of Actions, H1 2016 25
Number of Products by Stage and Mechanism of Actions, H1 2016 25
Number of Products by Routes of Administration, H1 2016 27
Number of Products by Stage and Routes of Administration, H1 2016 27
Number of Products by Molecule Types, H1 2016 29
Number of Products by Stage and Molecule Types, H1 2016 29
